Press Releases

Date	Title	PDF Version
Mar 02, 2023	Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
Nov 30, 2022	AstraZeneca showcases strength of hematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022
Nov 16, 2022	Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
Oct 27, 2022	ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
Oct 12, 2022	Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
Oct 03, 2022	Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
Sep 16, 2022	Danicopan (ALXN2040) add-on to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) met primary endpoint in ALPHA Phase III trial for patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis
Jun 23, 2022	ALXN1840 shows rapid and sustained improvement in copper mobilization from tissues, potentially closing treatment gaps for Wilson disease community
May 05, 2022	ULTOMIRIS® (ravulizumab-cwvz) met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder
Apr 28, 2022	ULTOMIRIS® (ravulizumab-cwvz) approved in the US for adults with generalized myasthenia gravis

Search